| 000 | 01089 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250517171124.0 | ||
| 264 | 0 | _c20180917 | |
| 008 | 201809s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(17)30627-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGruber, Karl | |
| 245 | 0 | 0 |
_aGenetic basis for response to cancer immunotherapy. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _c09 2017 |
||
| 300 |
_ae521 p. _bdigital |
||
| 500 | _aPublication Type: News | ||
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aCRISPR-Cas Systems |
| 650 | 0 | 4 | _aDatabases, Genetic |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aGene Editing _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aNeoplasms _xgenetics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Escape _xgenetics |
| 650 | 0 | 4 | _aExome Sequencing |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 18 _gno. 9 _gp. e521 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(17)30627-7 _zAvailable from publisher's website |
| 999 |
_c27483723 _d27483723 |
||